يحاول ذهب - حر

OpenAI, Microsoft Rift Hinges on How Smart AI Can Get

June 27, 2025

|

Mint Chennai

The future of the OpenAI-Microsoft partnership—one of the most storied in tech history—hinges in part on the meaning of an amorphous AI buzzword that divides many in the industry.

- Berber Jin

The contract between the tech partners, who have been locked in acrimonious negotiations, stipulates that when OpenAI's systems reach "artificial general intelligence," or AGI, the startup will be able to limit Microsoft's access to its future technology.

Microsoft is fighting hard to prevent that.

Many AI experts see AGI as the point at which generative AI systems achieve humanlike intelligence, but OpenAI and Microsoft are at odds over the issue.

OpenAI executives, including Sam Altman, believe they are close to being able to declare that their AI tools have achieved the AGI level of proficiency, according to people familiar with the matter.

Microsoft Chief Executive Satya Nadella has expressed skepticism that reaching such a benchmark is possible.

Their disagreement mirrors a debate among Silicon Valley's elite about just how sophisticated cutting-edge tools can become.

"We have a long-term, productive partnership that has delivered amazing AI tools for everyone. Talks are ongoing, and we are optimistic we will continue to build together for years to come," representatives for both companies said in a statement.

المزيد من القصص من Mint Chennai

Mint Chennai

Mint Chennai

Lenskart wants artificial intelligence to test your eyes

It expects AI-enabled eye testing to become the default foundational layer of eyecare delivery

time to read

3 mins

January 13, 2026

Mint Chennai

Mint Chennai

More companies to take a hit as labour codes debut

Reworked gratuity and leave encashments spell additional expenses for India Inc

time to read

2 mins

January 13, 2026

Mint Chennai

HC lifts ban on Zydus cancer biosimilar till patent expiry

In a relief for Zydus Lifesciences, a division bench of the Delhi High Court on Monday allowed the drugmaker to sell and market its biosimilar of the anticancer drug nivolumab in India, citing public interest.

time to read

2 mins

January 13, 2026

Mint Chennai

Trump’s investigation of Powell is also a warning to the next Fed chair

The criminal investigation into Federal Reserve Chair Jerome Powell isn’t ultimately about the Fed’s headquarters, or Powell, or even interest rates.

time to read

3 mins

January 13, 2026

Mint Chennai

Mint Chennai

States flag Almont-Kid syrup as tests find contaminants

Syrup found ‘Not of Standard Quality’ with contaminants like toxic ethylene glycol

time to read

1 mins

January 13, 2026

Mint Chennai

Mint Chennai

India at 100: Our choices today will define the next two decades

India's 2047 ambition is not guaranteed but achievable if we address all the potential pitfalls along our development path

time to read

4 mins

January 13, 2026

Mint Chennai

Now, inheritance works without probate—but why it still matters

Heirs can now act on a valid will without court cases, easing delays and unlocking assets in undisputed cases

time to read

6 mins

January 13, 2026

Mint Chennai

Why VCs have a new deep-tech playbook

where fundraising starts to drag,\" said Chand.

time to read

1 min

January 13, 2026

Mint Chennai

TCS, HCLTech deliver Q3 revenue surprise

clearer.

time to read

2 mins

January 13, 2026

Mint Chennai

Mint Chennai

US productivity is rising and it risks warping monetary policy

America's neutral rate ought to be going up but will the Fed listen?

time to read

3 mins

January 13, 2026

Listen

Translate

Share

-
+

Change font size